Nkarta reports FY2025 net loss of $104.1M; cash runway into 2029

Nkarta, Inc.

Cash, equivalents and investments $295.1M at Dec 31, 2025; expected to fund operations into 2029.
Full-year net loss $104.1M ($1.41 per share); Q4 net loss $27.4M ($0.37 per share).
NKX019 dose escalation advanced to 4 billion cells per dose in Ntrust-1 and Ntrust-2 trials.
Initial clinical data from Ntrust-1 and Ntrust-2 planned for presentation at a medical conference in 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Nkarta, Inc. reported the fourth quarter and year ended December 31, 2025 results: net income Net loss was $104.1 million, or $1.41 per basic and diluted share, for the full year 2025. Net loss was $27.4 million, o, EPS $1.41 per basic and diluted share (full year); $0.37 per basic and diluted share (fourth quarter).

Period: the fourth quarter and year ended December 31, 2025
Net income: Net loss was $104.1 million, or $1.41 per basic and diluted share, for the full year 2025. Net loss was $27.4 million, o
EPS: $1.41 per basic and diluted share (full year); $0.37 per basic and diluted share (fourth quarter)
Result: reported results

Exact text from the filing

On March 25, 2026, Nkarta, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0001787400-26-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.